NCCN guidelines recommend that patients with unresectable stage IIIA and IIIB NSCLC receive definitive concurrent chemoradiation followed by consolidation with durvalumab (anti-PD-L1)1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.